Leerink analyst Daina Graybosch notes that HARMONi-06 overall survival analysis from Akeso and partner Summit Therapeutics (SMMT) was selected as one of five plenary presentations at the ASCO annual meeting, which likely means that ivonescimab combined with chemotherapy drove a strong benefit in OS in first-line squamous non-small cell lung cancer. The positive investor reaction in Summit and BioNTech (BNTX) following the news is “warranted” given that OSis the “the most important and most uncertain outcome for the VEGF-A/PD-(L)1 bispecific class,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit partner selection for ASCO ‘likely a major positive,’ says Guggenheim
- Biotech Alert: Searches spiking for these stocks today
- Positioning Ivonescimab to Anchor a ~$200B PD-1xVEGF Market: Early NSCLC Validation and Commercial Head Start Support Buy Rating on Summit
- Summit Therapeutics initiated with a Buy at Stifel
- Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors